Float Short %

11.07

Margin Of Safety %

-19

Put/Call OI Ratio

0.06

EPS Next Q Diff

0.19

EPS Last/This Y

-6.34

EPS This/Next Y

2.93

Price

82.31

Target Price

95.92

Analyst Recom

1.23

Performance Q

25.77

Relative Volume

1.09

Beta

2.26

Ticker: PTGX

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-09	PTGX	88.58	0.06	0.01	14276
2025-12-10	PTGX	91.9	0.06	0.27	14572
2025-12-11	PTGX	92.18	0.06	0.00	14888
2025-12-12	PTGX	95.37	0.06	0.02	15041
2025-12-15	PTGX	94.82	0.06	0.01	15055
2025-12-16	PTGX	91.54	0.06	0.05	15082
2025-12-17	PTGX	89.44	0.06	0.02	15105
2025-12-18	PTGX	85.81	0.06	0.02	15312
2025-12-19	PTGX	86.04	0.06	0.02	15385
2025-12-22	PTGX	87.49	0.05	0.00	14469
2025-12-23	PTGX	88.81	0.05	0.00	14491
2025-12-26	PTGX	88.79	0.04	0.33	14613
2025-12-29	PTGX	87.85	0.04	0.68	14618
2025-12-30	PTGX	87.27	0.05	0.11	14657
2025-12-31	PTGX	87.27	0.05	0.20	15248
2026-01-02	PTGX	87.21	0.05	0.41	15296
2026-01-05	PTGX	84.78	0.05	0.12	15336
2026-01-06	PTGX	82.19	0.06	0.40	15434
2026-01-07	PTGX	82.26	0.06	0.11	15481
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-09	PTGX	88.56	-128.3	-	-1.87
2025-12-10	PTGX	91.37	-128.3	-	-1.87
2025-12-11	PTGX	92.20	-128.3	-	-1.87
2025-12-12	PTGX	95.25	-128.3	-	-1.87
2025-12-15	PTGX	94.79	-128.3	-	-1.87
2025-12-16	PTGX	94.79	-128.3	-	-1.87
2025-12-17	PTGX	89.33	-128.3	-	-1.87
2025-12-18	PTGX	85.70	-128.3	-	-1.87
2025-12-19	PTGX	86.03	-128.3	-	-1.87
2025-12-22	PTGX	87.70	-128.3	-	-1.87
2025-12-23	PTGX	88.93	-128.3	-	-1.87
2025-12-26	PTGX	88.84	-128.3	-	-1.87
2025-12-29	PTGX	87.92	-128.3	-	-1.87
2025-12-30	PTGX	87.27	-128.3	-	-1.87
2025-12-31	PTGX	87.32	-128.3	-	-1.87
2026-01-02	PTGX	87.22	-128.3	-	-1.87
2026-01-05	PTGX	84.27	-128.3	-	-1.87
2026-01-06	PTGX	82.25	-128.3	-	-1.87
2026-01-07	PTGX	82.31	-128.3	-	-1.87
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-09	PTGX	-2.98	-0.26	9.45
2025-12-10	PTGX	-2.98	-0.26	9.96
2025-12-11	PTGX	-2.98	-0.26	9.96
2025-12-12	PTGX	-2.43	-0.26	9.96
2025-12-15	PTGX	-2.43	-0.27	9.96
2025-12-16	PTGX	-2.44	-0.27	9.96
2025-12-17	PTGX	-2.44	-0.27	9.96
2025-12-18	PTGX	-2.44	-0.27	9.96
2025-12-19	PTGX	-2.44	-0.27	9.96
2025-12-22	PTGX	-2.44	-0.27	9.96
2025-12-23	PTGX	-2.44	-0.27	9.96
2025-12-26	PTGX	-2.44	-0.27	11.07
2025-12-29	PTGX	-2.44	-0.26	11.07
2025-12-30	PTGX	-2.44	-0.26	11.07
2025-12-31	PTGX	-2.44	-0.26	11.07
2026-01-02	PTGX	-2.44	-0.26	11.07
2026-01-05	PTGX	-2.44	-0.26	11.07
2026-01-06	PTGX	-2.44	-0.26	11.07
2026-01-07	PTGX	-2.44	-0.26	11.07
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-0.62

Avg. EPS Est. Current Quarter

-0.56

Avg. EPS Est. Next Quarter

-0.43

Insider Transactions

-2.44

Institutional Transactions

-0.26

Beta

2.26

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

66.79

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

14.7

Max Drawdown 5-Year %

-85.8

Target Price

95.92

P/E

130

Forward P/E

96.92

PEG

P/S

24.6

P/B

7.97

P/Free Cash Flow

80.8

EPS

0.63

Average EPS Est. Cur. Y

-1.87

EPS Next Y. (Est.)

1.06

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

21.94

Relative Volume

1.09

Return on Equity vs Sector %

-20

Return on Equity vs Industry %

-4.8

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Protagonist Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 128

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

stock quote shares PTGX – Protagonist Therapeutics Inc Stock Price stock today

news today PTGX – Protagonist Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch PTGX – Protagonist Therapeutics Inc yahoo finance google finance

stock history PTGX – Protagonist Therapeutics Inc invest stock market

stock prices PTGX premarket after hours

ticker PTGX fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: PTGX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y